Improved long-term survival of corpus cancer in Japan: A 40-year population-based analysis

Int J Cancer. 2022 Jan 15;150(2):232-242. doi: 10.1002/ijc.33799. Epub 2021 Sep 15.

Abstract

The incidence of uterine corpus cancer has been increasing globally due to increase in obesity. However, a detailed analysis of long-term epidemiological trends of corpus cancer in Japan, where obesity is relatively minimal, has not been conducted. In this retrospective, population-based study using the Osaka Cancer Registry, we analyzed 15 255 cases of corpus neoplasia registered between 1977 and 2016. We determined the age-standardized incidence, mortality, relative survival and conditional survival rates, and the treatment trends for corpus cancer over the last 40 years in Japan. The age-standardized incidence rate of corpus neoplasia increased sharply in 2000-2011 (APC = 9.9, 95% CI: 8.4-11.3), whereas the mortality rate trended to a much more modest increase (APC = 3.3, 95% CI: 2.7-3.8). Compared to 1977-2000, 10-year survival rates for post-2000 cases of localized and regional corpus cancers significantly improved (from 87.7% [95% CI: 85.8-89.4] to 94.2% [95% CI: 92.7-95.7] and from 47.5% [95% CI: 43.3-51.6] to 64.4% [95% CI: 61.0-67.6], respectively). This was largely associated with the significant increase in the percentage of localized and regional patients who received chemotherapy instead of radiation as an adjuvant therapy combined to surgery (P < .001 for both). We found that each histological type (endometrioid carcinoma, serous carcinoma, clear cell carcinoma and carcinosarcoma) has different characteristics of trend of age-standardized incidence rate, relative survival and distribution of extent of disease. In endometrioid carcinoma, the age-standardized incidence rate increased consistently after 1990, but the rate of increase was decreasing after 1997.

Keywords: adjuvant treatment; cancer registry; incidence; relative survival; uterine corpus cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma, Clear Cell / epidemiology
  • Adenocarcinoma, Clear Cell / mortality*
  • Adenocarcinoma, Clear Cell / pathology
  • Adenocarcinoma, Clear Cell / therapy
  • Adenocarcinoma, Mucinous / epidemiology
  • Adenocarcinoma, Mucinous / mortality*
  • Adenocarcinoma, Mucinous / pathology
  • Adenocarcinoma, Mucinous / therapy
  • Adult
  • Aged
  • Combined Modality Therapy
  • Cystadenocarcinoma, Serous / epidemiology
  • Cystadenocarcinoma, Serous / mortality*
  • Cystadenocarcinoma, Serous / pathology
  • Cystadenocarcinoma, Serous / therapy
  • Endometrial Neoplasms / epidemiology
  • Endometrial Neoplasms / mortality*
  • Endometrial Neoplasms / pathology
  • Endometrial Neoplasms / therapy
  • Female
  • Follow-Up Studies
  • Humans
  • Incidence
  • Japan / epidemiology
  • Middle Aged
  • Prognosis
  • Registries / statistics & numerical data*
  • Retrospective Studies
  • Survival Rate
  • Uterine Neoplasms / epidemiology
  • Uterine Neoplasms / mortality*
  • Uterine Neoplasms / pathology
  • Uterine Neoplasms / therapy